Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: A 12-month, randomized, naturalistic trial

Journal of Clinical Psychopharmacology

Volumn 33, Issue 4, 2013, Pages 533-537

  Cipriani, Andrea ^a   Accordini, Simone ^a   Nosè, Michela ^a   Purgato, Marianna ^a   Girlanda, Francesca ^a   Tansella, Michele ^a   Barbui, Corrado ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

antipsychotics; clozapine; combination strategies; randomized controlled trial; schizophrenia

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL;

ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; EVENT FREE SURVIVAL; HUMAN; ITALY; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT RESISTANT SCHIZOPHRENIA; TREATMENT WITHDRAWAL;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HALOPERIDOL; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; MULTIVARIATE ANALYSIS; PIPERAZINES; PROPORTIONAL HAZARDS MODELS; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879843228     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318296884f     Document Type: Article

References (23)

1. Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on clozapine in refractory schizophrenia. N Engl J Med. 1997;337: 809-815.
2. Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, et al. Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. Eur Psychiatry. 2005;20:409-415.
3. Remington G, Saha A, Chong SA, et al. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs. 2005;19:843-872.
4. Mouaffak F, Tranulis C, Gourevitch R, et al. Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia. Clin Neuropharmacol. 2006;29:28-33.
5. Paton C, Whittington C, Barnes TR. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis. J Clin Psychopharmacol. 2007;27: 198-204.
6. Chang JS, Ahn YM, Park HJ, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008;69:720-731.
7. Barbui C, Signoretti A, Mule S, et al. Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull. 2009;35:458-468.
8. Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev. 2009;(3):CD006324.
9. Fleischhacker WW, Heikkinen ME, Olié JP, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol. 2010;13:1115-1125.
10. Barbui C, Accordini S, Nosè M, et al. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial. J Clin Psychopharmacol. 2011;31:266-273.
11. Nosè M, Accordini S, Artioli P, et al. Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia. Trials. 2009;10:31.
12. Cipriani A, Barbui C. What is a clinical trial protocol? Epidemiol Psichiatr Soc. 2010;19:116-117.
13. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33.
14. Lukoff D, Nuechterlein KH, Ventura J. Manual for the Expanded Brief Psychiatric Rating Scale. Schizophr Bull. 1986;12:594-602.
15. Day JC, Wood G, Dewey M, et al. A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry. 1995;166:650-653.
16. Accordini S. An introduction to sample size calculations in clinical trials. Epidemiol Psichiatr Soc. 2007;16:299-301.
17. Rabe-Hesketh S, Skrondal A. Multilevel and Longitudinal Modeling Using Stata. 2nd ed. College Station, TX: Stata Press; 2008.
18. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
19. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371:1085-1097.
20. Barbui C, Cipriani A. What are evidence-based treatment recommendations? Epidemiol Psychiatr Sci. 2011;20:29-31.
21. Mule S, Cipriani A, Barbui C. Aripiprazole in addition to clozapine in partially responsive patients with schizophrenia: a critical review of case series. Clin Schizophr Relat Psych. 2008;1:341-347.
22. Sommer IE, Begemann MJ, Temmerman A, et al. Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull. 2012;38:1003-1011.
23. Muscatello MR, Bruno A, Pandolfo G, et al. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophr Res. 2011;127:93-99.